公司資料
Satsuma 股價、新聞與催化劑
- 股票代碼:
- STSA
- 交易所:
- NASDAQ
- 產業:
- Biopharma
- 所在地:
- United States
股價為何變動
Current closing-price context is not available for STSA.
公司概覽
業務概覽
Satsuma Pharmaceuticals was a migraine and CNS company focused on acute treatment delivery before its acquisition and restructuring. Its story centered on using inhaled delivery for migraine therapy.
所在地與產業分類
Headquartered in the United States and listed on NASDAQ before acquisition, Satsuma sat in specialty biotechnology.
商業模式特徵
The company depended on clinical validation, delivery technology, and the commercial opportunity in migraine care.
生技產業定位
Satsuma is best treated as a historical CNS and specialty-pharma case rather than a live catalyst name.
未來催化劑
- Satsuma’s catalyst set is now mostly legacy and transition-related, with any remaining update focused on how the migraine asset base is being handled. The market is no longer treating it like a fresh standalone growth story.
近期新聞
- 01
- 02
- 03
- 04
- 05
相似股票
商業成熟度、治療領域或催化劑模式相近的同業公司。